SoliPharma LLC • Pharmaceutical contract research organization. • Specializes in solid drug development, pre- formulation and formulation, commercialization enabling technology. • Incorporated in Delaware, US, with major lab spaces in Hangzhou BioHub in China. • ISO/IEC 17025:2005 accredited for testing and calibration. 1 TESTING CNAS L6384
Preformulation and formulation research for oral solid drug development
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SoliPharma LLC
• Pharmaceutical contract research organization.
• Specializes in solid drug development, pre-
formulation and formulation, commercialization
enabling technology.
• Incorporated in Delaware, US, with major lab
spaces in Hangzhou BioHub in China.
• ISO/IEC 17025:2005 accredited for testing and
calibration.
1
TESTING
CNAS L6384
2
SoliPharma Introduction
• Solipharma LLC, founded in 2010, is the first Chinese pharmaceutical
CRO focusing on solid state technology in drug development and
commercialization enabling research.
• Capabilities cover polymorph / salt form screening; form research and
crystallization process development; pre-formulation assessments; solid
dosage form strategy and process development.
• Talents include world-class experts and award-winning drug development
/ regulatory scientists. Ownership / access to state-of-art instruments
and facilities in one of the largest technology incubators in China.
Analytical Testing Pre-formulation Solid Form Studies Crystallization Development
Formulation Development Development Packages Instrumental Capacity Drug Development Partnership
3
SoliPharma Services
SoliPharma LLC ensures delivery of the highest quality research services on solid drug development, transparent reporting communication and potential IP value for pharmaceutical / biotechnology clients worldwide.
Analytical Testing P
hys
ical
Ch
arac
teri
zati
on
• Phase Analysis: XRD, Raman, IR
• Thermal Analysis: DSC, TGA, Hot Stage microscopy, Variable Temperature XRD
• Spectroscopy Analysis: Raman, IR, UV
• Bulk Analysis: Particle Size Distribution, Water Content, Moisture Sorption, Density
Qu
anti
tati
ve T
esti
ng
and
Met
ho
d D
evel
op
men
t
• HPLC Method Development and Validation
• Drug Substance Crystal Form Impurity Analysis
• Drug Substance Crystal Form Analysis in Drug Product
Stru
ctu
ral E
luci
dat
ion
• NMR Spectroscopy
• Single Crystal X-ray Structure Determination
• IR Spectroscopy
• Mass Spectroscopy
4
Solid Form Studies
Customized screening package for different development stage
Salt Screening and Stability
Polymorph Screening and Thermodynamic Stability
Cocrystal Screening and Stability
Identify the most preferred solid form for development
Solid Dispersion Screening
Draft technique disclosure document for patent application
Patent Application Drafting
5
Crystallization Development
HPLC method
development and
validation
Solvent screening
Solubility profile
Metastable zone analysis
Design space for critical
process parameters
Product characterization
and analysis
SOP for unit operations
Tech Package
Control drug substance
crystal form
Achieve target Impurity
profile
Recovery yield from the
mother liquor
Optimize bulk property
Improve process output
Process Development
Develop new
manufacturing
process to meet
target product
profile and IP
strategy
Optimize process
to meet target
product profile and
minimize cost
Strategic Goal
6
Pre-Formulation
Pre-formulation
• pKa, logP, logD determination
• Equilibrium and pH dependent solubility
• Solid and solution stability
• Dissolution
• Powder; Intrinsic
• Excipient compatibility
Physical Characterization
• Powder diffraction
• Thermal property
• Hygroscopicity / Water content
• IR/Raman spectroscopy
• UV spectrum
• Particle size distribution
• Microscopy
7
Preclinical formulation development and CTD dossier
Commercial formulation process development and CTD dossier
Process Development Goal
F2 value great than 60 as compared to reference
Compliant with Pharmacopeia; Draft CTD dossier
Tech Package for Formulation Development
HPLC method development and validation / Drug substance and reference drug product characterization and analysis / Dissolution method development
Excipient compatibility / stability
Packaging compatibility
Design space for critical process parameters / SOP for unit operations
• Hangzhou Economic & Technological Development Area ("HEDA") was ratified by the State Council as a national-grade development zone in April 1993, and exercises jurisdiction over an area of 104.7 km2. Currently 34 km2 of that has been equipped with complete infrastructure, beautiful environment, convenient supporting facilities and efficient government services.
• HEDA, a sub-center of Hangzhou Municipal City("Xiasha New Town"), is the ONLY national development area which collectively possesses industry base, export processing zone, university town and riverside residence area, etc.
• Bio-pharm industry is one of the four dominant industries within HEDA. The New Medicine Harbor has gathered a large number of well-known enterprises, and formed a distinctive industry cluster.
• The BASE has over 60 companies in 4 big sub-industries: biological medicine, new medical devices, modern Chinese medicines and new chemical substances.
• Rich technological and educational resources in the biggest provincial university town: 6 well known universities with world class programs in biological and pharmaceutical related sciences.
• Five public service platforms: Public Experimental Center Platform; Drug Crystal Formation R&D Platform; Bio-Tech Drugs Pilot Scale R&D Platform and etc.
• Policies of speeding up the development of bio-pharm industry in HEDA have launched, include "Acceleration Plan of the Development of Bio-Pharmaceutical Industry in HEDA".
• The Base has facilitated venture capital companies to work with HEDA. A "Bio-pharm Industry development fund" of RMB 200 Million has been set up for the first phase.